MedTrace Logo

Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany

NCT01454583 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15337

Last updated 2016-07-21

Study results available
· View outcomes & findings →

Summary

In Germany nearly half of the population present elevated values of blood pressure, with - as a result of lifestyle factors and a growing average age - further increasing numbers.

Consequences of arterial hypertension may be cardiovascular diseases, cerebrovascular events, and renal insufficiency. Thus, hypertension therapy focuses on the reduction of these complications.

The aims of the 3A-registry are the characterization of outpatients with hypertension, their diagnostic procedures and medical treatment (esp. with renin inhibitors), therapy compliance and success, clinical events, and an assessment of overall guideline adherence in the treatment of these patients.

Patients fulfilling the relevant criteria are enrolled and followed up by their general practitioner or medical specialist.

Conditions

  • Arterial Hypertension

Interventions

DRUG

Aliskiren

Aliskiren (Rasilez®, Novartis) is the first clinically available substance with direct renin inhibition (DRI) which effectively lowers blood pressure.

DRUG

ACE-I/ARB

DRUG

No RAS-inhibition

Sponsors & Collaborators

Principal Investigators

  • Uwe Zeymer, M.D. · Stiftung Institut für Herzinfarktforschung

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2009-10-31
Completion
2012-07-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01454583 on ClinicalTrials.gov